Relay Therapeutics, Inc.
Clinical trials sponsored by Relay Therapeutics, Inc., explained in plain language.
-
New precision drug targets Cancer's genetic weakness
Disease control Recruiting nowThis is a first-in-human study testing a new targeted drug called RLY-2608. It aims to find a safe and effective dose for patients with advanced solid tumors or breast cancer that have a specific genetic mutation called PIK3CA. The study will test the drug by itself and in combin…
Phase: PHASE1 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Targeted drug trial offers hope for rare growth disorders
Disease control Recruiting nowThis study is testing an experimental drug called RLY-2608 in adults and children with rare conditions that cause abnormal tissue overgrowth due to a specific genetic mutation. The research aims to find the right dose, check safety, and see if the drug can reduce the size of over…
Phase: PHASE2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for advanced breast cancer patients after standard treatment fails
Disease control Recruiting nowThis global Phase 3 trial is testing which of two drug combinations works better to control advanced breast cancer that has a specific genetic change (PIK3CA mutation) and has worsened after standard hormone therapy. It will enroll about 540 adults whose cancer has returned or sp…
Phase: PHASE3 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC